# Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

> **NCT02843659** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 45 (actual)

## Conditions studied

- Sjögren's Syndrome

## Interventions

- **DRUG:** BMS-931699
- **DRUG:** BMS-986142
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02843659
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-18
- **Primary completion:** 2017-07-24
- **Final completion:** 2017-07-24
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** Inability to meet protocol objectives
- **Last updated:** 2018-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02843659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02843659, "Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02843659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*